Concept · philosophy
Research ethics
6 studies4 discoveries
Research ethics is the justification of studies involving people: why a study is worth its risks, how consent and review work, and what researchers owe participants. The evidence here is mostly conceptual argument (social value, trust, end-of-life HIV research, committee outcomes), plus a document analysis of African genomics consent forms and an interview study of brain-research investigators.
Students often treat an approved protocol and a signed form as the whole of research ethics. These papers show the harder questions: whether a trial has enough value to justify risk, whether committees achieve anything measurable, and whether rules alone can handle conflicts researchers meet day to day.
Studies
6
Findings
6
6 supporting · 0 challenging · 1 qualifying citations
Open tensions
2
Currently
What we know
- An approval system existing is not proof it protects anyone.
- Ask what the tested intervention could be worth, not just whether the trial is well run.
- Consent design is shaped by funders' data-sharing rules, not only by participants' interests.
- Dying participants can be protected without being treated as unable to choose.
- Some research-ethics problems live in researchers' judgment, not in rulebooks.
Largest unresolved question
The social-value paper wants tighter formal review (a two-step committee test plus public input on value), while the virtue-ethics paper argues that the conflicts investigators actually face cannot be settled by general guidelines and need cultivated judgment. Both accept review; they differ on where the main ethical work should happen.
Common misconceptions
If an ethics committee approved the study, participants are protected.
The REC-outcomes paper argues we mostly lack evidence that committees achieve protections rather than paperwork, and the brain-research interviews show conflicts arising after approval.
Research ethics is just risk-benefit balancing for the participant.
In phase I and end-of-life research participants may get no direct benefit; the social-value paper replaces risk-benefit with risk-value, and the HIV paper counts fulfilling one's own altruistic aims as a kind of benefit.
Dying patients are automatically too vulnerable to join research.
The HIV cure-research paper calls blanket vulnerability labels paternalistic and proposes safeguards such as process consent by a non-treating clinician instead.
Related
Claim ledger
What the evidence shows
Drawn from 6 studies in this library. Mix labels say which citation roles are present; they are not a strength score. Supports means evidence for a finding; Challenges means evidence against a stated position; Qualifies marks scope.
An approval system existing is not proof it protects anyone.
Countries invest heavily in research ethics committees, but quality assurance has focused on processes and been nearly silent on outcomes, so we lack evidence that committees actually protect participants.
Ask what the tested intervention could be worth, not just whether the trial is well run.
Social value should be attached to the intervention being tested rather than to the trial, which removes an inconsistency (accepting higher risk in phase I trials said to have lower value); the authors propose a risk-value rather than risk-benefit assessment for first-in-human trials and a two-step review that first rejects interventions with no anticipated social value.
Consent design is shaped by funders' data-sharing rules, not only by participants' interests.
An analysis of H3Africa consent documents found most projects used broad consent, often because funders required data sharing, and explained genetics mainly through family inheritance.
Dying participants can be protected without being treated as unable to choose.
For HIV cure-related research with terminally ill volunteers (blood draws and rapid autopsy), the study's own investigators argue for ongoing 'process consent' taken by someone other than the treating doctor, and reject labelling all dying people as vulnerable as paternalistic; genuine altruism, they argue, weakens exploitation worries.
- Is it ethical to do HIV cure research on people who are dying?— Written by the protocol's own investigators; evidence that participation has been positive is anecdotal.
Some research-ethics problems live in researchers' judgment, not in rulebooks.
Interviews with 14 NIH BRAIN Initiative investigators doing invasive brain research found conflicts of interest from funding, publication and commercial pressure, and blurred roles when the treating surgeon also recruits; the authors argue such case-specific conflicts call for virtue-based 'neuroethical competencies' rather than more general guidelines.
Rules support trust; they cannot replace trustworthiness.
Consent and committee rules make research more reliable, but restoring public trust also requires researchers to be trustworthy and show goodwill toward vulnerable participants.
Debates
Tensions and limits
Some items are genuine disagreements on the same question. Others mark different assays, populations, or outcomes.
The social-value paper wants tighter formal review (a two-step committee test plus public input on value), while the virtue-ethics paper argues that the conflicts investigators actually face cannot be settled by general guidelines and need cultivated judgment. Both accept review; they differ on where the main ethical work should happen.
Evidence against
Qualified studies asking the same question reach different answers. The disagreement is listed, not scored.
The REC-outcomes paper doubts that committees are shown to protect anyone, while the social-value proposal adds new committee duties. These are compatible but in tension: adding tasks to a system whose outcomes are unmeasured.
The REC-outcomes paper doubts that committees are shown to protect anyone, while the social-value proposal adds new committee duties. These are compatible but in tension: adding tasks to a system whose outcomes are unmeasured.
PaperFren reads this as a limit on how far one study travels — different assays, populations, or outcomes — not a forced fight between papers.
Timeline
How understanding moved
Study years are when the paper was published. Evidence edits are dated changes to this page's claims. Explanations are when PaperFren added a Discovery — not a claim that the science happened that day.
2026
Concept page published
Research ethics
- Anti-doping surveillance would be unacceptable in any setting but this one
- Biobank consent is broken in one specific way, and the two proposed fixes contradict each other
- Research ethics committees are audited on process, not on whether anyone was protected
- Thirteen genomics consent forms, and what most of them left unspecified
Added a misconception
Research ethics is just risk-benefit balancing for the participant.
Added a misconception
Dying patients are automatically too vulnerable to join research.
- Added a scope qualifier
Is it ethical to do HIV cure research on people who are dying?
- Added a study that challenges this
Can virtue ethics help brain researchers handle conflicts?
- Added a supporting study
What makes risky early clinical trials worth doing?
- Added a supporting study
Is it ethical to do HIV cure research on people who are dying?
- Added a supporting study
Can virtue ethics help brain researchers handle conflicts?
- Added a supporting study
What makes risky early clinical trials worth doing?
- Added a supporting study
How do we know ethics committees work?
- Added a supporting study
What makes risky early clinical trials worth doing?
New claim
Social value should be attached to the intervention being tested rather than to the trial, which removes an inconsistency (accepting higher risk in phase I trials said to have lower value); the authors propose a risk-value rather than risk-benefit assessment for first-in-human trials and a two-step review that first rejects interventions with no anticipated social value.
New claim
For HIV cure-related research with terminally ill volunteers (blood draws and rapid autopsy), the study's own investigators argue for ongoing 'process consent' taken by someone other than the treating doctor, and reject labelling all dying people as vulnerable as paternalistic; genuine altruism, they argue, weakens exploitation worries.
New claim
Interviews with 14 NIH BRAIN Initiative investigators doing invasive brain research found conflicts of interest from funding, publication and commercial pressure, and blurred roles when the treating surgeon also recruits; the authors argue such case-specific conflicts call for virtue-based 'neuroethical competencies' rather than more general guidelines.
New tension
The social-value paper wants tighter formal review (a two-step committee test plus public input on value), while the virtue-ethics paper argues that the conflicts investigators actually face cannot be settled by general guidelines and need cultivated judgment. Both accept review; they differ on where the main ethical work should happen.
New tension
The REC-outcomes paper doubts that committees are shown to protect anyone, while the social-value proposal adds new committee duties. These are compatible but in tension: adding tasks to a system whose outcomes are unmeasured.
Change log
What changed
Dated edits to this page's evidence: studies added or removed from a claim, claims added or withdrawn, and new explanations tagged here. Coverage edits are distinct from reviewed research changes and corrections. Dates record PaperFren updates; study publication dates appear in the timeline.
Social value should be attached to the intervention being tested rather than to the trial, which removes an inconsistency (accepting higher risk in phase I trials said to have lower value); the authors propose a risk-value rather than risk-benefit assessment for first-in-human trials and a two-step review that first rejects interventions with no anticipated social value.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: What makes risky early clinical trials worth doing?
For HIV cure-related research with terminally ill volunteers (blood draws and rapid autopsy), the study's own investigators argue for ongoing 'process consent' taken by someone other than the treating doctor, and reject labelling all dying people as vulnerable as paternalistic; genuine altruism, they argue, weakens exploitation worries.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Is it ethical to do HIV cure research on people who are dying?
- Coverage updated · Added a scope qualifier: Is it ethical to do HIV cure research on people who are dying?
Interviews with 14 NIH BRAIN Initiative investigators doing invasive brain research found conflicts of interest from funding, publication and commercial pressure, and blurred roles when the treating surgeon also recruits; the authors argue such case-specific conflicts call for virtue-based 'neuroethical competencies' rather than more general guidelines.
- Coverage updated · New claim
- Coverage updated · Added a supporting study: Can virtue ethics help brain researchers handle conflicts?
The social-value paper wants tighter formal review (a two-step committee test plus public input on value), while the virtue-ethics paper argues that the conflicts investigators actually face cannot be settled by general guidelines and need cultivated judgment. Both accept review; they differ on where the main ethical work should happen.
- Coverage updated · New tension
- Coverage updated · Added a supporting study: What makes risky early clinical trials worth doing?
- Coverage updated · Added a study that challenges this: Can virtue ethics help brain researchers handle conflicts?
The REC-outcomes paper doubts that committees are shown to protect anyone, while the social-value proposal adds new committee duties. These are compatible but in tension: adding tasks to a system whose outcomes are unmeasured.
- Coverage updated · New tension
- Coverage updated · Added a supporting study: How do we know ethics committees work?
- Coverage updated · Added a supporting study: What makes risky early clinical trials worth doing?
Research ethics is just risk-benefit balancing for the participant.
- Coverage updated · Added a misconception
Dying patients are automatically too vulnerable to join research.
- Coverage updated · Added a misconception
- Thirteen genomics consent forms, and what most of them left unspecifiedEvidence: Emerging
- Anti-doping surveillance would be unacceptable in any setting but this oneEvidence: Emerging
- Coverage updated · Concept page published
Papers
6 studies in this library bear on Research ethics, ordered by citations.
- How do we know ethics committees work?
Countries pour resources into RECs, but quality assurance has been nearly silent on outcomes, so we may have processes without real protections for participants or communities.
- Do research rules restore trust?
Kerasidou argues that consent and ethics-committee rules make research more reliable, but restoring trust also requires trustworthiness and goodwill toward the vulnerable.
- How H3Africa consent forms explain genomics
Most H3Africa projects used broad consent, often because funders required data sharing, while forms explained genetics mainly through family inheritance.
- What makes risky early clinical trials worth doing?
The authors argue that 'social value' should refer only to the improvement a tested intervention is expected to bring to patients, and that trials of interventions lacking such value should not expose people to risk at all.
- Is it ethical to do HIV cure research on people who are dying?
The authors argue that dying people with HIV can ethically donate samples and their bodies to cure research that cannot help them, provided consent, altruism and vulnerability are handled with care.
- Can virtue ethics help brain researchers handle conflicts?
Researchers who put electrodes in human brains face tangled conflicts of interest that rules alone cannot resolve, so the authors argue for training ethical skills and judgment.
Compare studies
Select 2–10 studies. Design and N are labels, not a ranking.
Nothing selected yet.
Questions
What is still open
The social-value paper wants tighter formal review (a two-step committee test plus public input on value), while the virtue-ethics paper argues that the conflicts investigators actually face cannot be settled by general guidelines and need cultivated judgment. Both accept review; they differ on where the main ethical work should happen.
The REC-outcomes paper doubts that committees are shown to protect anyone, while the social-value proposal adds new committee duties. These are compatible but in tension: adding tasks to a system whose outcomes are unmeasured.
Ask PaperFren about Research ethics
Study this conceptflashcards and short-answer questions
Why do ordinary risk-benefit frameworks struggle with first-in-human trials, and what does the social-value paper propose instead?
Phase I participants rarely benefit, and if phase I trials are said to have less value than phase III, it is hard to explain accepting higher risks in them. The social-value paper resolves this by locating value in the intervention, not the trial. It proposes a risk-value assessment and a two-step review: reject interventions with no anticipated social value, then weigh value, translational prospect and validity against risk, with patients and the public helping judge value.
What does the interview study of brain-research investigators suggest about the limits of guidelines?
Fourteen investigators described conflicts from grant and publication pressure and blurred roles when a treating surgeon also recruits patients. The authors argue these are case-specific and cannot be settled by general rules, so they propose building neuroethical competencies and closer collaboration with ethicists. The claim is argued rather than tested: the sample is small and self-reported, and no evidence is given that virtue training improves decisions.